Ami Organics’ initial public offer will be opened for subscription on 1 September 2021. The said IPO would continue till 3 September. As per the DRHP, this public offer will comprise a new share issue worth Rs. 200 crores and an OFS of nearly 6.06 million shares by its shareholders and promoters.
Here’s more on this recent development.
As per IPO market reports, Ami Organics will follow a timeline that is similar to Vijaya Diagnostics. In other words, this is a tentative timeline of how this upcoming public offer will be carried out:
Ami Organics has set its IPO price band at Rs. 603 – Rs. 610 apiece. This company’s shares will be listed on both NSE and BSE. Also, the face value of its equity shares will be set at Rs. 10 apiece. The market lot of this upcoming IPO is set at 24 shares and so is its minimum order quantity. Note that, a retail investor can apply for a maximum of 13 lots, i.e., 312 shares amounting to Rs. 190,320 at its cut off price.
Here’s a break up of Ami Organics IPO’s offer for sale (OFS):
Other than this, a maximum of 3.05 million shares will be offered by Kiranben Girishbhai Chovatia.
Hence, this company is likely to raise nearly Rs. 570 crores at its upper-end of price band. As per reports, Ami Organics plans to move ahead with a pre-IPO placement offer of a maximum of Rs. 100 crores.
So, how does this specialty chemicals maker wish to use its IPO proceeds?
The IPO will be used to:
As of March 2021, this company’s net debt was recorded as Rs. 218.73 crores. In the fiscal year ending on March 2021, Ami Organics recorded revenue of Rs. 340.61 crores against Rs. 239.64 crores from the previous year. Similarly, the net profit of this company for the same period was recorded at Rs. 53.99 crores against the previous year’s Rs. 27.47 crores.
This upcoming IPO will be headed by Intensive Fiscal Services Pvt Ltd., Axis Capital Ltd., and Ambit Pvt Ltd as the issue’s lead managers.
In essence, Ami Organics is a leading R&D driven manufacturer of specialty chemicals that has found wide application across several industries.
Ami Organics’s pharma intermediates are extensively used to manufacture NCEs and APIs to multiple MNPC companies catering to large and rapidly growing markets of Japan, China, Latin America, Europe, and the USA.
Its well-diversified portfolio and strong presence in the domestic and international market offer it a competitive edge over its peers. That said, currently, the market is in favour of pharma. This could act as a catalyst for the success of this upcoming IPO.
Then again, it is always recommended to analyse the company’s potential, especially its opportunities and limitations, to make an informed decision.
Get all the latest updates on the upcoming IPO of 2021 on the Angel One portal.
Chetankumar Chhaganlal Vaghasia, Parul Chetankumar Vaghasia, Nareshkumar Ramjibhai Patel, and Shital Nareshbhai Patel are the promoters of Ami Organics.
Ami Organics will have a book-built issue type.
Link Intime India Private Ltd. is the registrar of Ami Organics.
The profit after tax for 31 March 21 was Rs. 539.99 million.
We're Live on WhatsApp! Join our channel for market insights & updates
Enjoy ₹0 Account Opening Charges
Join our 2 Cr+ happy customers